Company Description

TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. Their lead clinical candidate, MYMD-1® is an orally available, next-generation TNF-alpha inhibitor with the potential to transform the way TNF-alpha based diseases are treated.